[go: up one dir, main page]

MX2019010263A - Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas. - Google Patents

Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas.

Info

Publication number
MX2019010263A
MX2019010263A MX2019010263A MX2019010263A MX2019010263A MX 2019010263 A MX2019010263 A MX 2019010263A MX 2019010263 A MX2019010263 A MX 2019010263A MX 2019010263 A MX2019010263 A MX 2019010263A MX 2019010263 A MX2019010263 A MX 2019010263A
Authority
MX
Mexico
Prior art keywords
methods
making
nicotine formulations
dry powder
powder formulations
Prior art date
Application number
MX2019010263A
Other languages
English (en)
Inventor
Stenzler Alex
Han Steve
Slutsky Arthur
Ellis Steven
Zamel Noe
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/452,133 external-priority patent/US10149844B2/en
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of MX2019010263A publication Critical patent/MX2019010263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacture Of Tobacco Products (AREA)

Abstract

La presente invención proporciona formulaciones de polvo seco que comprenden nicotina, métodos de uso de las mismas y métodos para fabricarlas. Las formulaciones de polvo seco pueden comprender además excipientes, agentes terapéuticos y compuestos saborizantes. Las formulaciones de polvo seco pueden fabricarse mediante procesos secos y procesos húmedos.
MX2019010263A 2017-03-07 2018-03-07 Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas. MX2019010263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/452,133 US10149844B2 (en) 2015-09-16 2017-03-07 Inhalable nicotine formulations, and methods of making and using thereof
PCT/IB2018/051482 WO2018163085A1 (en) 2017-03-07 2018-03-07 Inhalable nicotine formulations, and methods of making and using thereof

Publications (1)

Publication Number Publication Date
MX2019010263A true MX2019010263A (es) 2019-10-09

Family

ID=61731727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010263A MX2019010263A (es) 2017-03-07 2018-03-07 Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas.

Country Status (9)

Country Link
EP (1) EP3592352A1 (es)
JP (2) JP7680823B2 (es)
KR (1) KR20190126772A (es)
CN (1) CN110300588A (es)
CA (1) CA3048677A1 (es)
IL (1) IL268458A (es)
MX (1) MX2019010263A (es)
RU (1) RU2770039C2 (es)
WO (1) WO2018163085A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220395015A1 (en) * 2019-11-14 2022-12-15 Philip Morris Products S.A. Improved tobacco flavoured dry powder formulation
KR20230079011A (ko) * 2020-09-03 2023-06-05 필립모리스 프로덕츠 에스.에이. 저 흡습성 동결 건조 활성 분말 조성물
CN112841709B (zh) * 2021-01-20 2022-11-25 深圳市艾普生物科技有限公司 一种尼古丁盐的制备方法及应用
CN113880802A (zh) * 2021-11-09 2022-01-04 深圳萨特瓦生物科技有限公司 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法
EP4609856A1 (en) * 2022-10-27 2025-09-03 KT&G Corporation Dry powder inhaler stick containing cough suppressant and dry powder inhaler comprising same
CN117322671A (zh) * 2023-11-01 2024-01-02 东莞市吉纯生物技术有限公司 一种烟碱脂质体及其制备方法与电子雾化液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017663A1 (en) * 1992-03-10 1993-09-16 Fisons Plc Pharmaceutical inhalation compositions
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA03001092A (es) * 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
WO2003024396A2 (en) * 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US7832397B2 (en) * 2005-12-28 2010-11-16 Philip Morris Usa Inc. Aerosol powder delivery device
WO2008069970A2 (en) * 2006-12-01 2008-06-12 Aradigm Corporation Nicotine formulations, kits and systems and methods for their use
MX355833B (es) * 2011-08-01 2018-05-02 Univ Monash Metodo y formulacion para inhalacion.
CA2944471C (en) * 2014-04-08 2020-03-31 Sansa Corporation (Barbados) Inc. Nicotine formulations and methods of making the same
FR3035826B1 (fr) * 2015-05-07 2018-11-16 Saint-Gobain Glass France Vitrage de vehicule comprenant une platine pour la fixation de plusieurs accessoires, platine et procede de fixation.
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) * 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
CN105770862B (zh) * 2016-04-22 2022-01-11 北京三元基因药业股份有限公司 干扰素的干粉吸入剂
US11458093B2 (en) * 2016-06-30 2022-10-04 Philip Morris Products S.A. Nicotine particles

Also Published As

Publication number Publication date
CN110300588A (zh) 2019-10-01
CA3048677A1 (en) 2018-09-13
RU2770039C2 (ru) 2022-04-14
EP3592352A1 (en) 2020-01-15
IL268458A (en) 2019-09-26
JP7680823B2 (ja) 2025-05-21
RU2019128062A3 (es) 2021-05-21
WO2018163085A1 (en) 2018-09-13
KR20190126772A (ko) 2019-11-12
JP2020510002A (ja) 2020-04-02
JP2024150531A (ja) 2024-10-23
RU2019128062A (ru) 2021-04-07

Similar Documents

Publication Publication Date Title
PH12018500544A1 (en) Inhalable nicotine formulations, and methods of making and using thereof
MX2019010263A (es) Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas.
MX2023010042A (es) Polinucleotidos moduladores.
SG11202011761XA (en) Nicotine formulation
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
PH12017500762A1 (en) Proflavor delivery particles
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
NZ724756A (en) An inhalable rapamycin formulation for treating age-related conditions
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
TW201613901A (en) New compounds
IL266047A (en) Methods and preparations for the treatment of Fabry disease
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MY176176A (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
MY186229A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
MX389399B (es) Una formulación de rapamicina inhalable para el tratamiento de hipertensión pulmonar.
IL258139A (en) Nicotine compositions and methods for their preparation and use
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX378607B (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
EA036036B1 (ru) Композиции, содержащие циклоспорин
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.